Natural Macrolides
Historically, natural agents were the first to appear in clinical practice. A prominent representative is oleandomycin, produced by Streptomyces antibioticus. Its antimicrobial spectrum is similar to that of erythromycin, but it is less potent. Consequently, the drug requires frequent administration (4–6 times daily). To slow down the development of bacterial resistance, oleandomycin is often combined with tetracycline—a combination known as oleandomycin-tetracycline.
Natural 16-membered macrolides (spiramycin, josamycin, midecamycin) deserve special attention. Their primary clinical advantages include:
- Retaining activity against staphylococcal and streptococcal strains that have already developed resistance to erythromycin.
- Better tolerability (significantly lower incidence of dyspeptic disorders).
- Stable bioavailability, as food intake has virtually no effect on their absorption.
Spiramycin (administered 2–3 times daily) is widely used in dentistry for treating gingivitis and periodontal infections. It is also the drug of choice for toxoplasmosis. Josamycin and midecamycin are administered every 8 hours. Notably, midecamycin acetate is a semisynthetic prodrug: it is absorbed and penetrates tissues much more efficiently than its native form.
Semisynthetic 14-Membered Macrolides
This group includes roxithromycin and clarithromycin. Their molecules were modified to solve the primary drawback of early macrolides—unstable pharmacokinetics.
These newer agents are readily absorbed from the gastrointestinal tract regardless of food intake, achieve high tissue concentrations, and possess a prolonged duration of action. This makes dosing regimens much more convenient for patients: roxithromycin is taken 1–2 times daily, while clarithromycin is taken every 12 hours (available for both oral and intravenous administration).
Clarithromycin has several specific indications:
- Eradication of Helicobacter pylori in peptic ulcer disease.
- Treatment and prophylaxis of opportunistic infections in HIV-positive patients (specifically those caused by Mycobacterium avium complex).
- Treatment of infections caused by intracellular pathogens (mycoplasma, chlamydia, legionella).
Azalides (Azithromycin)
Azithromycin is a 15-membered semisynthetic macrolide. Because a nitrogen atom is incorporated into its lactone ring, the drug is classified into a separate structural subclass known as azalides.
Compared to erythromycin, azithromycin's spectrum of activity is shifted: it is less active against staphylococci, but exhibits greater efficacy against gram-negative flora (enterobacteria, Haemophilus influenzae) and intracellular agents (toxoplasma, legionella).
The pharmacokinetics of azithromycin are unique. It achieves record-breaking tissue concentrations among all class representatives, and its elimination half-life ranges from 35 to 55 hours. The primary clinical advantage of this kinetic profile is the ability to administer the antibiotic just once daily.
Adverse Effects
Although macrolides are considered among the safest antibacterial agents, their administration can be accompanied by characteristic adverse reactions. Typical side effects include:
- Allergic reactions of varying severity.
- Dyspeptic disorders: patients frequently complain of nausea and epigastric discomfort, which occurs because these drugs can stimulate gastrointestinal motility.
- Hepatotoxicity: potential development of cholestatic hepatitis and elevated plasma transaminases.
- Ototoxicity: rare cases of hearing impairment.